| XLS |
|
|
|
|
|
| ||
|
€ million |
Q2 2012 |
Q2 2011* |
Jan.–June |
Jan.–June | ||
| ||||||
|
Profit after tax |
–60.5 |
–86.8 |
114.6 |
254.7 | ||
|
Available-for-sale financial assets |
|
|
|
| ||
|
Fair value adjustments |
0.1 |
4.1 |
0.1 |
29.3 | ||
|
Reclassification to income statement |
– |
–22.8 |
– |
–27.2 | ||
|
Deferred taxes |
– |
–0.2 |
– |
0.6 | ||
|
Changes recognized in equity |
0.1 |
–18.9 |
0.1 |
2.7 | ||
|
Derivative financial instruments |
|
|
|
| ||
|
Fair value adjustments |
–76.6 |
1.4 |
–51.0 |
13.2 | ||
|
Reclassification to income statement |
12.3 |
–5.7 |
54.3 |
–3.6 | ||
|
Deferred taxes |
11.3 |
0.4 |
1.2 |
–0.2 | ||
|
Changes recognized in equity |
–53.0 |
–3.9 |
4.5 |
9.4 | ||
|
Remeasurement of the net defined benefit liability |
|
|
|
| ||
|
Changes in remeasurement |
–9.8 |
0.1 |
–9.8 |
2.0 | ||
|
Deferred taxes |
–1.9 |
0.3 |
–1.9 |
0.1 | ||
|
Changes recognized in equity |
–11.7 |
0.4 |
–11.7 |
2.1 | ||
|
Exchange differences on translating foreign operations |
|
|
|
| ||
|
Changes taken directly to equity |
61.4 |
26.7 |
42.0 |
–42.4 | ||
|
Reclassification to income statement |
– |
– |
– |
3.5 | ||
|
Changes recognized in equity |
61.4 |
26.7 |
42.0 |
–38.9 | ||
|
Gains/losses recognized immediately in equity |
–3.2 |
4.3 |
34.9 |
–24.7 | ||
|
Comprehensive income |
–63.8 |
–82.5 |
149.5 |
230.0 | ||
|
of which attributable to Merck KGaA shareholders |
–65.5 |
–83.5 |
145.5 |
228.2 | ||
|
of which attributable to non-controlling interest |
1.7 |
1.0 |
4.0 |
1.8 | ||